• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

整合 bulk-RNA 测序和单细胞测序分析,以描绘富含腺苷的肿瘤微环境景观,并开发一个与腺苷相关的预后标志物,用于预测肺腺癌的免疫治疗反应。

Integrating bulk-RNA sequencing and single-cell sequencing analyses to characterize adenosine-enriched tumor microenvironment landscape and develop an adenosine-related prognostic signature predicting immunotherapy in lung adenocarcinoma.

机构信息

School of Medicine, Anhui University of Science and Technology, Chongren Building, No 168, Taifeng St, Huainan, People's Republic of China.

Anhui Province Engineering Laboratory of Occupational Health and Safety, Anhui University of Science and Technology, Huainan, People's Republic of China.

出版信息

Funct Integr Genomics. 2024 Jan 24;24(1):19. doi: 10.1007/s10142-023-01281-z.

DOI:10.1007/s10142-023-01281-z
PMID:38265702
Abstract

The adenosine-signaling axis has been recognized as an important immunomodulatory pathway in tumor immunity. However, the biological role of the adenosine-signaling axis in the remodeling of the tumor microenvironment (TME) in lung adenocarcinoma (LUAD) remains unclear. Here, we quantified adenosine signaling (ado_sig) in LUAD samples using the GSVA method and assessed the prognostic value of adenosine in LUAD. Afterward, we explored the heterogeneity of the tumor-immune microenvironment at different adenosine levels. In addition, we analyzed the potential biological pathways engaged by adenosine. Next, we established single-cell transcriptional profiles of LUAD and analyzed cellular composition and cell-cell communication analysis under different adenosine microenvironments. Moreover, we established adenosine-related prognostic signatures (ARS) based on comprehensive bioinformatics analysis and evaluated the efficacy of ARS in predicting immunotherapy. The results demonstrated that adenosine signaling adversely impacted the survival of immune-enriched LUAD. The high-adenosine microenvironment exhibited elevated pro-tumor-immune infiltration, including M2 macrophages and displayed notably increased epithelial-mesenchymal transition (EMT) transformation. Furthermore, adenosine signaling displayed significant associations with the expression patterns and prognostic value of immunomodulators within the TME. Single-cell sequencing data revealed increased fibroblast occupancy and a prominent activation of the SPP1 signaling pathway in the high adenosine-signaling microenvironment. The ARS exhibited promising effectiveness in prognostication and predicting immunotherapy response in LUAD. In summary, overexpression of adenosine can cause a worsened prognosis in the LUAD with abundant immune infiltration. Moreover, increased adenosine levels are associated with pro-tumor-immune infiltration, active EMT transformation, pro-tumor angiogenesis, and other factors promoting cancer progression, which collectively contribute to the formation of an immunosuppressive microenvironment. Importantly, the ARS developed in this study demonstrate high efficacy in evaluating the response to immunotherapy.

摘要

腺苷信号通路已被认为是肿瘤免疫中重要的免疫调节途径。然而,腺苷信号通路在肺腺癌(LUAD)肿瘤微环境(TME)重塑中的生物学作用仍不清楚。在这里,我们使用 GSVA 方法量化了 LUAD 样本中的腺苷信号(ado_sig),并评估了腺苷在 LUAD 中的预后价值。之后,我们探索了不同腺苷水平下肿瘤免疫微环境的异质性。此外,我们分析了腺苷所涉及的潜在生物学途径。接下来,我们建立了 LUAD 的单细胞转录图谱,并在不同腺苷微环境下分析了细胞组成和细胞间通讯分析。此外,我们基于全面的生物信息学分析建立了腺苷相关的预后标志物(ARS),并评估了 ARS 在预测免疫治疗中的疗效。结果表明,腺苷信号对富含免疫的 LUAD 的生存产生了不利影响。高腺苷微环境表现出升高的促肿瘤免疫浸润,包括 M2 巨噬细胞,并表现出明显增加的上皮-间充质转化(EMT)转化。此外,腺苷信号与 TME 中免疫调节剂的表达模式和预后价值显著相关。单细胞测序数据显示,在高腺苷信号微环境中,成纤维细胞的占有率增加,并且 SPP1 信号通路明显激活。ARS 在 LUAD 的预后预测和免疫治疗反应预测方面表现出良好的效果。总之,腺苷的过度表达可导致富含免疫浸润的 LUAD 预后恶化。此外,增加的腺苷水平与促肿瘤免疫浸润、活跃的 EMT 转化、促肿瘤血管生成和其他促进癌症进展的因素相关,这些因素共同导致了免疫抑制微环境的形成。重要的是,本研究中开发的 ARS 在评估免疫治疗反应方面表现出很高的效果。

相似文献

1
Integrating bulk-RNA sequencing and single-cell sequencing analyses to characterize adenosine-enriched tumor microenvironment landscape and develop an adenosine-related prognostic signature predicting immunotherapy in lung adenocarcinoma.整合 bulk-RNA 测序和单细胞测序分析,以描绘富含腺苷的肿瘤微环境景观,并开发一个与腺苷相关的预后标志物,用于预测肺腺癌的免疫治疗反应。
Funct Integr Genomics. 2024 Jan 24;24(1):19. doi: 10.1007/s10142-023-01281-z.
2
Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.鉴定免疫激活相关基因特征,以预测肺腺癌的预后和免疫治疗疗效。
Front Immunol. 2023 Jul 7;14:1217590. doi: 10.3389/fimmu.2023.1217590. eCollection 2023.
3
Integrated bulk and single-cell RNA sequencing identifies an aneuploidy-based gene signature to predict sensitivity of lung adenocarcinoma to traditional chemotherapy drugs and patients' prognosis.整合 bulk 和单细胞 RNA 测序,确定了基于非整倍体的基因特征,可预测肺腺癌对传统化疗药物的敏感性和患者的预后。
PeerJ. 2024 Jun 24;12:e17545. doi: 10.7717/peerj.17545. eCollection 2024.
4
Single-cell and Bulk RNA-Seq reveal angiogenic heterogeneity and microenvironmental features to evaluate prognosis and therapeutic response in lung adenocarcinoma.单细胞和 bulk RNA-Seq 揭示血管生成异质性和微环境特征,以评估肺腺癌的预后和治疗反应。
Front Immunol. 2024 Feb 8;15:1352893. doi: 10.3389/fimmu.2024.1352893. eCollection 2024.
5
Prediction of prognosis, immunogenicity and efficacy of immunotherapy based on glutamine metabolism in lung adenocarcinoma.基于肺腺癌谷氨酰胺代谢预测预后、免疫原性和免疫治疗疗效。
Front Immunol. 2022 Aug 11;13:960738. doi: 10.3389/fimmu.2022.960738. eCollection 2022.
6
Integrated analysis of single-cell RNA-seq and bulk RNA-seq reveals immune suppression subtypes and establishes a novel signature for determining the prognosis in lung adenocarcinoma.单细胞 RNA-seq 和批量 RNA-seq 的综合分析揭示了免疫抑制亚型,并建立了一个新的特征,用于确定肺腺癌的预后。
Cell Oncol (Dordr). 2024 Oct;47(5):1697-1713. doi: 10.1007/s13402-024-00948-4. Epub 2024 Apr 15.
7
Integration of multiple key molecules in lung adenocarcinoma identifies prognostic and immunotherapeutic relevant gene signatures.肺腺癌中多个关键分子的整合鉴定出与预后和免疫治疗相关的基因特征。
Int Immunopharmacol. 2020 Jun;83:106477. doi: 10.1016/j.intimp.2020.106477. Epub 2020 Apr 8.
8
Comprehensive analysis of the immunogenic cell death-related signature for predicting prognosis and immunotherapy efficiency in patients with lung adenocarcinoma.全面分析免疫细胞死亡相关特征,预测肺腺癌患者的预后和免疫治疗效果。
BMC Med Genomics. 2023 Aug 8;16(1):184. doi: 10.1186/s12920-023-01604-w.
9
Comprehensive analysis of PPP4C's impact on prognosis, immune microenvironment, and immunotherapy response in lung adenocarcinoma using single-cell sequencing and multi-omics.基于单细胞测序和多组学技术综合分析 PPP4C 对肺腺癌预后、免疫微环境和免疫治疗反应的影响
Front Immunol. 2024 Jul 4;15:1416632. doi: 10.3389/fimmu.2024.1416632. eCollection 2024.
10
H3K4me3-related lncRNAs signature and comprehensive analysis of H3K4me3 regulating tumor immunity in lung adenocarcinoma.H3K4me3 相关 lncRNAs 特征分析及 H3K4me3 调控肺腺癌肿瘤免疫的综合分析
Respir Res. 2023 May 3;24(1):122. doi: 10.1186/s12931-023-02418-1.

引用本文的文献

1
Adenosine signaling in tumor-associated macrophages and targeting adenosine signaling for cancer therapy.肿瘤相关巨噬细胞中的腺苷信号传导以及靶向腺苷信号传导用于癌症治疗
Cancer Biol Med. 2024 Dec 3;21(11):995-1011. doi: 10.20892/j.issn.2095-3941.2024.0228.

本文引用的文献

1
Peripheral CD4 memory T cells predict the efficacy of immune checkpoint inhibitor therapy in patients with non-small cell lung cancer.外周血 CD4 记忆 T 细胞预测免疫检查点抑制剂治疗非小细胞肺癌患者的疗效。
Sci Rep. 2023 Jul 4;13(1):10807. doi: 10.1038/s41598-023-37736-3.
2
A2aR on lung adenocarcinoma cells: A novel target for cancer therapy via recruiting and regulating tumor-associated macrophages.肺腺癌细胞上的 A2aR:通过募集和调节肿瘤相关巨噬细胞用于癌症治疗的新靶点。
Chem Biol Interact. 2023 Sep 1;382:110543. doi: 10.1016/j.cbi.2023.110543. Epub 2023 May 30.
3
Evidence that cervical cancer cells cultured as tumorspheres maintain high CD73 expression and increase their protumor characteristics through TGF-β production.
有证据表明,作为肿瘤球培养的宫颈癌细胞保持高水平的 CD73 表达,并通过 TGF-β 产生增加其促肿瘤特性。
Cell Biochem Funct. 2022 Oct;40(7):760-772. doi: 10.1002/cbf.3742. Epub 2022 Sep 7.
4
Pan-sarcoma characterization of lncRNAs in the crosstalk of EMT and tumour immunity identifies distinct clinical outcomes and potential implications for immunotherapy.泛癌种长链非编码 RNA 特征分析 EMT 与肿瘤免疫的串扰,鉴定出不同的临床结局和对免疫治疗的潜在影响。
Cell Mol Life Sci. 2022 Jul 16;79(8):427. doi: 10.1007/s00018-022-04462-4.
5
Identification of prognostic candidate signatures by systematically revealing transcriptome characteristics in lung adenocarcinoma with differing tumor microenvironment immune phenotypes.通过系统揭示具有不同肿瘤微环境免疫表型的肺腺癌中转录组特征,鉴定预后候选标志物。
Aging (Albany NY). 2022 Jun 7;14(11):4786-4818. doi: 10.18632/aging.204112.
6
Programmed death ligand 1 signals in cancer cells.程序性死亡配体 1 在癌细胞中的信号转导。
Nat Rev Cancer. 2022 Mar;22(3):174-189. doi: 10.1038/s41568-021-00431-4. Epub 2022 Jan 14.
7
Multi-Omics Analysis Showed the Clinical Value of Gene Signatures of C1QC and SPP1 TAMs in Cervical Cancer.多组学分析显示C1QC和SPP1肿瘤相关巨噬细胞的基因特征在宫颈癌中的临床价值。
Front Immunol. 2021 Jul 6;12:694801. doi: 10.3389/fimmu.2021.694801. eCollection 2021.
8
Smoking and Incidence of Colorectal Cancer Subclassified by Tumor-Associated Macrophage Infiltrates.吸烟与按肿瘤相关巨噬细胞浸润分类的结直肠癌发病率
J Natl Cancer Inst. 2022 Jan 11;114(1):68-77. doi: 10.1093/jnci/djab142.
9
The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response.与预后和免疫治疗反应相关的上皮-间质转化与免疫逃逸之间串扰的泛癌格局。
NPJ Precis Oncol. 2021 Jun 22;5(1):56. doi: 10.1038/s41698-021-00200-4.
10
Upregulation of Is a Marker for Poor Lung Cancer Prognosis and Contributes to Cancer Progression and Cisplatin Resistance.的上调是肺癌预后不良的标志物,并促进癌症进展和顺铂耐药。 (注:原文中“Upregulation of ”后面缺少具体内容)
Front Cell Dev Biol. 2021 Apr 29;9:646390. doi: 10.3389/fcell.2021.646390. eCollection 2021.